Literature DB >> 2878462

Serum concentrations and clinical effect of zuclopenthixol in acutely disturbed, psychotic patients treated with zuclopenthixol acetate in Viscoleo.

A Amdisen, T Aaes-Jørgensen, N J Thomsen, V T Madsen, M S Nielsen.   

Abstract

Zuclopenthixol acetate, 5%, in Viscoleo was administered IM to 19 acutely disturbed, psychotic patients in doses of 50-150 mg. Fifteen patients received one injection, whereas four of the patients had two or three injections, usually with intervals of 3 days. The zuclopenthixol concentrations in serum were measured in series of samples taken from each patient during a 3-day period following the injection. In patients given identical doses serum concentrations of about the same order were obtained. Significant and good correlations were found between dose and maximal serum concentration and between dose and area under the serum concentration curve. The average serum concentration curve obtained when adjusting the data to a 100 mg dose has a maximum of 41 ng/ml after about 36 h, decreasing to 15 ng/ml after 72 h. A dose of 50-150 mg zuclopenthixol acetate in Viscoleo appeared to be sufficient for controlling the symptoms for most acutely disturbed, psychotic patients. The frequency of side effects, including extrapyramidal reactions, was low and the adverse reactions mostly mild, indicating that the risks for severe complications generally might be minimal. With a rapid onset of action, few and mild side effects, good tolerability at the injection site, and a duration of effect of 2-3 days, zuclopenthixol acetate in Viscoleo appears to offer advantages compared to conventional neuroleptic treatment in patients in whom an acute, calming effect is desired.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2878462     DOI: 10.1007/bf00179201

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  10 in total

1.  High-dose neuroleptics: uncontrolled clinical practice confirms controlled clinical trials.

Authors:  P Bollini; A Andreani; F Colombo; C Bellantuono; P Beretta; A Arduini; T Galli; G Tognoni
Journal:  Br J Psychiatry       Date:  1984-01       Impact factor: 9.319

2.  A specific method for assay of drug levels in serum of patients treated with clopenthixol decanoate injections.

Authors:  K F Overø
Journal:  Acta Psychiatr Scand Suppl       Date:  1980

3.  Specific high-performance liquid chromatographic method for estimation of the cis(Z)- and trans(E)-isomers of clopenthixol and a N-dealkyl metabolite.

Authors:  T Aaes-Jørgensen
Journal:  J Chromatogr       Date:  1980-08-08

4.  Serum levels of the isomers of clopenthixol in patients given cis(Z)-clopenthixol or cis(Z)/trans(E)-clopenthixol.

Authors:  T Aaes-Jørgensen; A Gravem; A Jørgensen
Journal:  Acta Psychiatr Scand Suppl       Date:  1981

5.  Pharmacokinetic studies on clopenthixol decanoate; a comparison with clopenthixol in dogs and rats.

Authors:  T Aaes-Jorgensen; K F Overo; K P Bogeso; A Jorgensen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1977-08

6.  Serum concentrations of the isomers of clopenthixol and a metabolite in patients given cis(Z)-clopenthixol decanoate in viscoleo.

Authors:  T Aaes-Jørgensen; L Kirk; E Petersen; P Danneskiold-Samsøe; A Jørgensen
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

7.  Plasma levels of perphenazine and its major metabolites during simultaneous treatment with anticholinergic drugs.

Authors:  L B Hansen; J Elley; T R Christensen; N E Larsen; J Naestoft; E F Hvidberg
Journal:  Br J Clin Pharmacol       Date:  1979-01       Impact factor: 4.335

8.  Rapid treatment of acute psychotic symptoms with high- and low-dose haloperidol. Behavioral considerations.

Authors:  R Neborsky; D Janowsky; E Munson; D Depry
Journal:  Arch Gen Psychiatry       Date:  1981-02

9.  Haloperidol for acute schizophrenic patients. An evaluation of three oral regimens.

Authors:  P T Donlon; J T Hopkin; J P Tupin; J J Wicks; M Wahba; A Meadow
Journal:  Arch Gen Psychiatry       Date:  1980-06

10.  Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. III. Serum levels.

Authors:  A Jrgensen; K F Overø
Journal:  Acta Psychiatr Scand Suppl       Date:  1980
  10 in total
  4 in total

Review 1.  Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring.

Authors:  A E Balant-Gorgia; L Balant
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

2.  Hypouricemic effect of zuclopenthixol: a potential marker of drug compliance?

Authors:  M Bloch; E Gur; A Y Shalev
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 3.  Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses.

Authors:  Kaushadh Jayakody; Roger Carl Gibson; Ajit Kumar; Shalmini Gunadasa
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

4.  An open trial of zuclopenthixol in management of acute psychoses : a multicentered study.

Authors:  J Fernandes; P V Pradhan; P Choudhury; S Chatterji; J Pereira; H Shah; H A Bhinderwala; D M Bhadlikar; R Radhakrishanan
Journal:  Indian J Psychiatry       Date:  1999-07       Impact factor: 1.759

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.